Abstract
Progress in the field of chemotherapy of cancer depends decisively on whether we succeed in developing compounds with a higher selectivity of the antitumoral action and thus with a greater therapeutic range, i.e., less dangerous in clinical use. This has been the guiding principle in the work of the Asta research teams for over 30 years.
“Die Idee ist nicht so ohnmächtig, es nur bis zur Idee zu bringen”
G.W.F. Hegel
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brock, N. Chem.Exp.Technol. 3, 441–448 (1977)
Druckrey, H, Raabe, S. Klin.Wschr. 30, 882–884 (1952)
Arnold, H, Bourseaux, F, Brock, N. Nature 181, 931 (1958)
Arnold, H, Bourseaux, F, Crock, N. Arzneim.-Forsch. (Drug Res.) 11, 143 (1961)
Brock, N. Experimental Basis of Cancer Chemotherapy. In: K. Hellmann and T.A. Connors (Eds), Chemotherapy Vol. 7, 1976, Plenung Publishing Corp., New York, p. 19
Brock, N. Pharmakologische Grundlagen der Krebs-Chemotherapie. In: A. Georgii, Verhandlungen der Deutschen Krebsgesellschaft,Band 1, 1978, Gustav Fischer Verlag, Stuttgart — New York, p. 15
Brock, N, Potei, J. Arzneim.-Forsch. (Drug Res.) 24, 1149 (1974)
Brock, N. Cancer Treat.Rep. 60, 301–307 (1976)
Brock, N, Hohorst, HJ. Z. Krebsforsch. 88, 185–215 (1977)
Peter, G, Wagner, T, Hohorst, HJ. Cancer Treat.Reports 60, 429–435 (1976)
Hohorst, HJ, Bielicki, L, Voelcker, G. The Mode of Action of Cyclophosphamide. 9th int. Symposium on the Biological Characterization of Human Tumours, 1981, Bologna.
Brock, N, Niemeyer, U, Pohl, J, Scheffler, G. Stabilised primary metabolites of oxazaphosphorine cytostatics with high cytotoxic specificity and cancerotoxic selectivity needing no enzymatic activation. Third NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1981, Brussels
Brock, N, Pohl, J, Stekar, J. Europ.J.Cancer 17, 595–607 (1981)
Brock, N, Pohl, J, Stekar, J. Europ.J.Cancer Clin. Onco1. 17, 1155–1168 (1981)
Brock, N, Pohl, J, Stekar, J, Scheef, W. Europ.J.Cancer Clin.Oncol. 1982 in print
Ormstad, K, Orrenius, S, LSstbom, T, Uenara, N, Pohl, J, Brock, N. 1982 in print
Brock, N, Stekar, J, Pohl, J, Niemeyer, U, Scheffler, G. Arzneirn.Forsch. (Drug Res.) 29, 659–661 (1979)
Pohl, J, Brock, N, Stekar, J. Toxicology, Pharmacology and Interactions of Sodium 2-mercaptoethane sulfonate (Mesna). 12th int. Chemotherapy Congress, 1981, Florence
Habs, M, Schmdhl, D, Brock, N. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-rnercaptoethane sulfonate (mesna) and disodium 2,2’-dithio-bis-ethane sulfonate (dimesna). 13th int. Cancer Congress, 1982, Seattle
Kaufmann, B, Wegmann, W. Schweiz.med.Wschr. 111 540–545 (1981)
Hill, D.L. A review of cyclophosphamide. 1975. Charles C. Thomas Publ., Springfield, Ill.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Additional information
Dedicated to Prof. Dr. Herbert Oelschläger for his 60th birthday. This work was supported by the Bundesministerium für Forschung und Technologie, Bonn.
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, The Hague, Boston, London
About this chapter
Cite this chapter
Brock, N. (1983). Oxazaphosphorine Cytostatics: Structure—Activity Relationships, Selectivity and Metabolism, Regional Detoxification. In: Reinhoudt, D.N., Connors, T.A., Pinedo, H.M., van de Poll, K.W. (eds) Structure-Activity Relationships of Anti-Tumour Agents. Developments in Pharmacology, vol 3. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-6798-4_12
Download citation
DOI: https://doi.org/10.1007/978-94-009-6798-4_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-009-6800-4
Online ISBN: 978-94-009-6798-4
eBook Packages: Springer Book Archive